Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 2/24/17)$49.69
Total Net Assets (As of 1/31/17)$3.23B
Annual Expense Ratio
(As of fiscal year end 9/30/16)
GROSS 0.94%
NET 0.94%

Morningstar Fee Level
(As of 1/31/17)
Fee Level Group
(out of 296 funds)
Specialty No Load

Performance (As of 12/31/16)
1 Year-12.39%
3 Year8.54%
5 Year19.94%
10 Year12.23%
Morningstar (As of 1/31/17)
CategoryUS Fund Health
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

125 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Straight Talk

Quarterly Commentary - Q4 2016

EXECUTIVE SUMMARY

Global health care stocks slid during the period as investors shifted to more economically sensitive sectors.

The Fund underperformed its benchmark, weighed down, in part by its pharmaceuticals and biotechnology holdings.

We view the steady number of drug filings as a signal that innovation remains strong within the sector.

FUND MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996

Ethan Lovell

Ethan Lovell

Fund Manager since 2016
Industry since 1994